Cybin announced that the United States Patent and Trademark Office or USPTO has granted U.S. patent 11,834,410 in support of its CYB003 program. The patent, which is expected to provide exclusivity until at least 2041, includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program, CYB003, as well as claims directed toward the therapeutic treatment of major depressive disorder or MDD , treatment-resistant depression, and alcohol use disorder. “Securing robust patent protection for our proprietary products is a top priority, and we are pleased to announce this additional U.S. patent supporting our CYB003 program,” said Doug Drysdale, Chief Executive Officer of Cybin. “Last week, we shared positive Phase 2 topline safety and efficacy data for CYB003 in MDD. In addition to the rapid, robust and statistically significant reduction in depression symptoms observed three weeks following a single 12 milligram dose of CYB003 compared to placebo, we also saw a sustained improvement at six weeks, as well as impressive response and remission rates of 79% for patients who received two doses. We are extremely pleased with the data and the potential to deliver meaningfully improved treatment options for people with mental health disorders and are eager to progress our CYB003 program through the next regulatory steps.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYBN:
- Cybin to discuss efficacy data for CYB003 for major depressive disorder
- Cybin initiated with a Buy at Alliance Global Partners
- Cybin price target lowered to $5 from $10 at H.C. Wainwright
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Cybin reports Q2 net income (C$11.9M) vs (C$10M) last year